[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629671":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":108,"collaborators":11,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":112,"sex":118,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":11,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":46,"whyStopped":11,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Regeneron Pharmaceuticals","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1 - Low Dose","EXPERIMENTAL",null,[13],"Drug: Alirocumab",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm 2 - Medium Dose",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Arm 3 - High Dose",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Arm 4 - Control Dose",[13],[24],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Alirocumab","Administered per the protocol",[9,15,18,21],[30,31,32],"Praluent®","REGN727","SAR236553",[34],{"name":35,"affiliation":5,"role":36},"Clinical Trial Management","STUDY_DIRECTOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"Clinical Trials Administrator","CONTACT","844-734-6643","clinicaltrials@regeneron.com",[44,58,68,78,88,98],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":11},"Precision Clinical Research","RECRUITING","Sunrise","Florida","33351","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-80.1131,26.13397,{"lat":56,"lon":55},{"facility":59,"status":46,"city":60,"state":61,"zip":62,"country":50,"countryCode":51,"cosmosGeoPoint":63,"geoPoint":67,"contacts":11},"Balanced Life Health Care Solutions","Lawrenceville","Georgia","30046",{"type":53,"coordinates":64},[65,66],-83.98796,33.95621,{"lat":66,"lon":65},{"facility":69,"status":46,"city":70,"state":71,"zip":72,"country":50,"countryCode":51,"cosmosGeoPoint":73,"geoPoint":77,"contacts":11},"Mercury Street Medical Group, PLLC","Butte","Montana","59701",{"type":53,"coordinates":74},[75,76],-112.53474,46.00382,{"lat":76,"lon":75},{"facility":79,"status":46,"city":80,"state":81,"zip":82,"country":50,"countryCode":51,"cosmosGeoPoint":83,"geoPoint":87,"contacts":11},"Velocity Clinical Research - Durham","Durham","North Carolina","27701",{"type":53,"coordinates":84},[85,86],-78.89862,35.99403,{"lat":86,"lon":85},{"facility":89,"status":46,"city":90,"state":91,"zip":92,"country":50,"countryCode":51,"cosmosGeoPoint":93,"geoPoint":97,"contacts":11},"Velocity Clinical Research, Medford","Medford","Oregon","97504",{"type":53,"coordinates":94},[95,96],-122.87559,42.32652,{"lat":96,"lon":95},{"facility":99,"status":46,"city":100,"state":101,"zip":102,"country":50,"countryCode":51,"cosmosGeoPoint":103,"geoPoint":107,"contacts":11},"Velocity Clinical Research Dallas","Dallas","Texas","75230",{"type":53,"coordinates":104},[105,106],-96.80667,32.78306,{"lat":106,"lon":105},{"type":109,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100629671","phase-2-a-study-to-see-how-safe-and-effective-alirocumab-is-when-given-weekly-to-adult-participants-who-have-hypercholesterolemia-100629671",false,"NCT07477704","A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia","A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Weekly Alirocumab in Adults With Hypercholesterolemia","ASCEND-QW","Key Inclusion Criteria:\n\n1\\. Participant has elevated LDL-C level, as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Participant plans to initiate or change dose of lipid-lowering therapy\n2. Use of any PCSK9 inhibitors\n\nNOTE: Other Protocol-Defined Inclusion\u002FExclusion Criteria Apply","ALL","18 Years","80 Years",{"count":122,"type":123},420,"ESTIMATED","INTERVENTIONAL",[126],"PHASE2","This study is researching an experimental drug called alirocumab, referred to as \"study drug\". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).\n\nThe aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia.\n\nThe study is looking at several other research questions, including:\n\n* What side effects may happen from taking the study drug once a week\n* How much study drug is in the blood at different times",[129],"Hypercholesterolemia",[131,132],"Obesity","Elevated Low-Density Lipoprotein Cholesterol (LDL-C) Levels","2026-06-30",{"date":135,"type":136},"2026-07-01","ACTUAL",{"date":138,"type":136},"2026-06-17",{"date":140,"type":123},"2027-02-23",{"name":5,"class":6},6]